Loading..

ChemoCentryx, Inc. (CCXI) Report Analysis

Corporate Events

Negative

ChemoCentryx, Inc. Appoints Yi Ching Yau as Sen...

2022-06-09 20:41:00

ChemoCentryx, Inc. announced that Yi Ching Yau, age 46, has been appointed Senior Vice President, Finance and Principal Accounting Officer of ...

Positive

Chemocentryx Inc. Reports Safety Results Availa...

2022-06-06 12:30:00

ChemoCentryx, Inc. announced the presentation of safety results from the ongoing Phase I clinical study of CCX559, the Company’s highly potent...

Neutral

ChemoCentryx, Inc. Presents at DGE's 2nd KOL & ...

2022-06-01 11:06:00

ChemoCentryx, Inc. Presents at DGE's 2nd KOL & Thought Leader Engagement Summit, Jun-01-2022 through Jun-02-2022. Presentation Date & Speakers...

Neutral

Dynamic Global Events LLC, DGE's 2nd KOL & Thou...

2022-06-01 10:15:00

Dynamic Global Events LLC, DGE's 2nd KOL & Thought Leader Engagement Summit, Jun 01, 2022 through Jun 02, 2022.

Neutral

ChemoCentryx, Inc. Presents at European Allianc...

2022-05-31 20:05:00

ChemoCentryx, Inc. Presents at European Alliance of Associations for Rheumatology (EULAR) Congress 2022, Jun-02-2022 10:35 AM.

Neutral

ChemoCentryx, Inc. Presents at EULAR Congress 2...

2022-05-31 20:05:00

ChemoCentryx, Inc. Presents at EULAR Congress 2022, Jun-01-2022 through Jun-04-2022. Venue: Bella Center Copenhagen, Center Boulevard 5, Copen...

Neutral

ChemoCentryx, Inc. Presents at The 2022 ASCO An...

2022-05-31 20:05:00

ChemoCentryx, Inc. Presents at The 2022 ASCO Annual Meeting, Jun-05-2022 08:00 AM. Venue: McCormick Place, Chicago, Illinois, United States.

Negative

ChemoCentryx Announces Changes to its Board of ...

2022-05-31 12:30:00

ChemoCentryx, Inc. announced changes to the composition of its Board of Directors. David E. Wheadon, M.D., has been elected to the Board as an...

Neutral

ChemoCentryx, Inc. Presents at H.C. Wainwright ...

2022-05-16 12:30:00

ChemoCentryx, Inc. Presents at H.C. Wainwright Global Investment Conference 2022, May-24-2022 12:30 PM. Venue: Fontainebleau Miami Beach Hotel...

Neutral

The International Society For Pharmacoeconomics...

2022-05-11 19:48:00

The International Society For Pharmacoeconomics And Outcomes Research Inc, ISPOR 2022, May 15, 2022 through May 18, 2022. Venue: Washington D....

Neutral

ChemoCentryx, Inc. Presents at American Thoraci...

2022-05-11 12:30:00

ChemoCentryx, Inc. Presents at American Thoracic Society 2022 International Conference, May-17-2022 03:15 PM. Venue: San Francicso, California...

Neutral

ChemoCentryx, Inc. Presents at ISPOR 2022, May-...

2022-05-11 12:30:00

ChemoCentryx, Inc. Presents at ISPOR 2022, May-17-2022 05:30 PM. Venue: Washington D.C., District Of Columbia, United States.

Neutral

European Renal Association - European Dialisi a...

2022-05-11 12:30:00

European Renal Association - European Dialisi and Transplant Association, 59thERA Conference (European Renal Association), May 19, 2022 throug...

Neutral

ChemoCentryx, Inc. Presents at 59thERA Conferen...

2022-05-11 12:30:00

ChemoCentryx, Inc. Presents at 59thERA Conference (European Renal Association), May-20-2022 05:00 PM.

Neutral

ChemoCentryx, Inc., Q1 2022 Earnings Call, May 05, 2022

2022-04-28 12:30:00

ChemoCentryx, Inc., Q1 2022 Earnings Call, May 05, 2022

Neutral

ChemoCentryx, Inc. to Report Q1, 2022 Results o...

2022-04-28 12:30:00

ChemoCentryx, Inc. announced that they will report Q1, 2022 results After-Market on May 05, 2022

Positive

ChemoCentryx, Inc. Reports Pharmacokinetic and ...

2022-04-13 12:30:00

ChemoCentryx, Inc. announced the presentation of preclinical data and initial pharmacokinetic (PK) and pharmacodynamic data from the ongoing P...

Neutral

ChemoCentryx, Inc., Annual General Meeting, May...

2022-04-05 20:09:00

ChemoCentryx, Inc., Annual General Meeting, May 26, 2022, at 10:00 Pacific Daylight. Location: at the company’s headquarters, located at 835 I...

Neutral

ChemoCentryx, Inc. Presents at Wells Fargo Annu...

2022-03-29 20:00:00

ChemoCentryx, Inc. Presents at Wells Fargo Annual Biotech Forum, Apr-12-2022 . Venue: Miami, Florida, United States. Speakers: Susan M. Kanaya...

Neutral

Wells Fargo Securities, LLC, Wells Fargo Annual...

2022-03-29 11:02:00

Wells Fargo Securities, LLC, Wells Fargo Annual Biotech Forum, Apr 12, 2022 through Apr 13, 2022. Venue: Miami, Florida, United States.

Neutral

H.C. Wainwright & Co., LLC, H.C. Wainwright Glo...

2022-02-28 18:21:00

H.C. Wainwright & Co., LLC, H.C. Wainwright Global Investment Conference 2022, May 23, 2022 through May 26, 2022. Venue: Fontainebleau Miami B...

Neutral

American Society Of Clinical Oncology, Inc., th...

2021-12-10 06:32:00

American Society Of Clinical Oncology, Inc., The 2022 ASCO Annual Meeting, Jun 03, 2022 through Jun 07, 2022. Venue: McCormick Place, Chicago,...

Neutral

ChemoCentryx, Inc. Presents at Piper Sandler 33...

2021-11-22 15:06:00

ChemoCentryx, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference, Nov-29-2021 . Venue: New York, New York, United States.

Neutral

American Thoracic Society, Inc, American Thorac...

2021-11-13 09:53:00

American Thoracic Society, Inc, American Thoracic Society 2022 International Conference, May 13, 2022 through May 18, 2022. Venue: San Francic...

Positive

ChemoCentryx, Inc Announces Positive Recommenda...

2021-11-12 13:30:00

ChemoCentryx, Inc. announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positi...

Neutral

ChemoCentryx, Inc. Presents at Stifel 2021 Virt...

2021-11-10 13:00:00

ChemoCentryx, Inc. Presents at Stifel 2021 Virtual Healthcare Conference, Nov-17-2021 02:00 PM. Venue: New York, New York, United States. Spea...

Neutral

ChemoCentryx, Inc. Presents at Piper Sandler 33...

2021-11-10 13:00:00

ChemoCentryx, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov-22-2021 10:00 AM. Speakers: Thomas ...

Neutral

ChemoCentryx, Inc., Q3 2021 Earnings Call, Nov 09, 2021

2021-11-02 14:04:00

ChemoCentryx, Inc., Q3 2021 Earnings Call, Nov 09, 2021

Neutral

ChemoCentryx, Inc. to Report Q3, 2021 Results o...

2021-11-02 14:04:00

ChemoCentryx, Inc. announced that they will report Q3, 2021 results After-Market on Nov 09, 2021

Neutral

SVB Leerink LLC, 11th SVB Leerink Annual Global...

2021-10-29 14:57:00

SVB Leerink LLC, 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb 14, 2022 through Feb 18, 2022. Venue: New York, New York, Unit...

Neutral

Piper Sandler Companies, Piper Sandler 33rd Ann...

2021-10-25 10:00:00

Piper Sandler Companies, Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov 22, 2021.

Negative

Chemocentryx Appoints Rita I. Jain, M.D. as Exe...

2021-10-11 12:30:00

ChemoCentryx, Inc. announced the appointment of Rita I. Jain, M.D., as Executive Vice President, Chief Medical Officer. In this role, she will...

Neutral

ChemoCentryx, Inc. - Special Call

2021-10-08 11:00:00

ChemoCentryx, Inc. - Special Call

Positive

ChemoCentryx, Inc. Announces FDA Approval of TA...

2021-10-08 11:00:00

ChemoCentryx, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved TAVNEOS (avacopan), an orally administered selectiv...

Positive

ChemoCentryx Announces Approval in Japan of TAV...

2021-09-27 12:30:00

ChemoCentryx, Inc. announced that Kissei Pharmaceutical Co. Ltd. has received approval from the Japanese Ministry of Health, Labor, and Welfar...

Neutral

ChemoCentryx, Inc. Presents at H.C. Wainwright ...

2021-09-02 12:33:00

ChemoCentryx, Inc. Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-13-2021 07:00 AM. Venue: Lotte New York Palace Ho...

Neutral

ChemoCentryx, Inc. Presents at Citi’s 16th Annu...

2021-09-01 19:46:00

ChemoCentryx, Inc. Presents at Citi’s 16th Annual BioPharma Virtual Conference, Sep-08-2021 . Venue: New York, United States.

Neutral

ChemoCentryx, Inc. has filed a Shelf Registrati...

2021-08-10 00:00:00

ChemoCentryx, Inc. has filed a Shelf Registration in the amount of $13.87 million. Security Name: Common Stock Securities Offered: 950,000...

Neutral

ChemoCentryx, Inc. Presents at Canaccord Genuit...

2021-08-04 12:30:00

ChemoCentryx, Inc. Presents at Canaccord Genuity 41st Annual Growth Conference, Aug-11-2021 05:00 PM. Speakers: Thomas J. Schall, Founder, Pre...

Neutral

ChemoCentryx, Inc. to Report Q2, 2021 Results o...

2021-08-02 12:36:00

ChemoCentryx, Inc. announced that they will report Q2, 2021 results After-Market on Aug 09, 2021

Neutral

ChemoCentryx, Inc., Q2 2021 Earnings Call, Aug 09, 2021

2021-08-02 12:30:00

ChemoCentryx, Inc., Q2 2021 Earnings Call, Aug 09, 2021

Neutral

ChemoCentryx, Inc. Presents at Wells Fargo 2021...

2021-07-22 14:24:00

ChemoCentryx, Inc. Presents at Wells Fargo 2021 Virtual Healthcare Conference, Sep-09-2021 04:40 PM. Speakers: Susan M. Kanaya, Executive VP, ...

Neutral

Wells Fargo Securities, LLC, Wells Fargo 2021 V...

2021-07-22 09:08:00

Wells Fargo Securities, LLC, Wells Fargo 2021 Virtual Healthcare Conference, Sep 09, 2021 through Sep 10, 2021.

Neutral

Stifel, Nicolaus & Company, Incorporated, Stife...

2021-07-08 08:44:00

Stifel, Nicolaus & Company, Incorporated, Stifel 2021 Virtual Healthcare Conference, Nov 15, 2021 through Nov 17, 2021. Venue: New York, New ...

Positive

ChemoCentryx, Inc. Announces Filing of Amendmen...

2021-07-06 12:30:00

ChemoCentryx, Inc. announced that, following consultations with the U.S. Food and Drug Administration (FDA), it filed an amendment to its New ...

Negative

Rosen Law Firm Encourages ChemoCentryx, Inc. In...

2021-07-04 15:15:00

Rosen Law Firm reminded purchasers of the securities of ChemoCentryx, Inc. between November 26, 2019 and May 6, 2021, inclusive (the “Class Pe...

Negative

ChemoCentryx, Inc. Appoints Yi Ching Yau as Senior Vice President, Finance and Principal Accounting Officer

2022-06-09 20:41:00

ChemoCentryx, Inc. announced that Yi Ching Yau, age 46, has been appointed Senior Vice President, Finance and Principal Accounting Officer of the company, effective as of June 6, 2022. Prior to joining the Company, Ms. Yau served as the Chief Accounting Officer for BridgeBio Pharma, Inc. from October 2019 to March 2022. Prior to BridgeBio Pharma, Inc., Ms. Yau was Vice President, Finance at Nektar Therapeutics from May 2018 to October 2019 and Corporate Controller and Assistant Treasurer at Theravance Biopharma, Inc. from October 2013 to May 2018. From 2001 to 2013, Ms. Yau worked at Ernst & Young LLP, most recently as Senior Manager, and is a California Certified Public Accountant and Charted Accountant of Singapore. She holds a Bachelor of Accountancy from Nanyang Technological University, Singapore.

Positive

Chemocentryx Inc. Reports Safety Results Available from Ongoing Phase I Trial of Orally Administered Pd-L1 Inhibitor, Ccx559, At the 2022 American Society of Clinical Oncology (Asco) Annual Meeting

2022-06-06 12:30:00

ChemoCentryx, Inc. announced the presentation of safety results from the ongoing Phase I clinical study of CCX559, the Company’s highly potent, orally administered PD-L1 checkpoint inhibitor, in patients with advanced solid tumors during a poster session at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. In the ASCO poster titled, Results From an Ongoing Phase 1 Dose-Escalation Study of CCX559, an Orally Administered Small Molecule PD-L1 Inhibitor, in Patients With Advanced Solid Tumors (abstract #2593), ChemoCentryx reported patient baseline characteristics and safety data available from the ongoing study as of April 27, 2022, from the first 13 patients enrolled across four dose cohorts: 30 mg, 60 mg, 120 mg, and 180 mg. The first-in-human Phase I study is assessing CCX559 in patients with a range of advanced solid tumors. Ten of the 13 patients enrolled have received at least two or more prior lines of systemic therapy. The primary objectives of the study are to evaluate the safety and tolerability, and to inform dose selection for the planned Phase Ib/II clinical trial. To date, there have been no dose limiting toxicities (DLTs) or treatment-related serious or severe (= grade 3) adverse events (AEs) reported. Two patients receiving 120 mg once daily CCX559 presented with three probable immune-related AEs, which provides supportive evidence of immune activation. There have been no treatment-related AEs reported in more than one patient. The ASCO poster also includes pharmacokinetic (PK) and pharmacodynamic (PD) data that build on the positive findings presented during the 2022 American Association for Cancer Research (AACR) Annual Meeting in April, providing evidence that CCX559 is pharmacologically active and 120 mg once daily is a therapeutically relevant dose. Results presented during ASCO indicate continued dose-dependent PK exposure at Day 1 for CCX559. The mean exposure at 120 mg (n=10) remains in line with preclinical projections and continues to increase at the 180 mg level (n=1). Consistent with approved antibody inhibitors of PD-L1, CCX559 demonstrates immunomodulatory activity in first cycle of treatment. ChemoCentryx expects to present additional findings from this ongoing Phase I study at major oncology conferences through 2022. The tumor types being evaluated in the Phase I study are not known to be responsive to treatment with anti-PD-1/PD-L1 therapies, and the Company plans to advance CCX559 into a Phase Ib/II clinical trial to measure anti-tumor effects of CCX559 more directly during the second half of 2022.

Neutral

ChemoCentryx, Inc. Presents at DGE's 2nd KOL & Thought Leader Engagement Summit, Jun-01-2022 through Jun-02-2022

2022-06-01 11:06:00

ChemoCentryx, Inc. Presents at DGE's 2nd KOL & Thought Leader Engagement Summit, Jun-01-2022 through Jun-02-2022. Presentation Date & Speakers: Jun-01-2022, Irene von Hennigs, VP, Medical Affairs.

Neutral

Dynamic Global Events LLC, DGE's 2nd KOL & Thought Leader Engagement Summit, Jun 01, 2022 through Jun 02, 2022

2022-06-01 10:15:00

Dynamic Global Events LLC, DGE's 2nd KOL & Thought Leader Engagement Summit, Jun 01, 2022 through Jun 02, 2022.

Neutral

ChemoCentryx, Inc. Presents at European Alliance of Associations for Rheumatology (EULAR) Congress 2022, Jun-02-2022 10:35 AM

2022-05-31 20:05:00

ChemoCentryx, Inc. Presents at European Alliance of Associations for Rheumatology (EULAR) Congress 2022, Jun-02-2022 10:35 AM.

Neutral

ChemoCentryx, Inc. Presents at EULAR Congress 2022, Jun-01-2022 through Jun-04-2022

2022-05-31 20:05:00

ChemoCentryx, Inc. Presents at EULAR Congress 2022, Jun-01-2022 through Jun-04-2022. Venue: Bella Center Copenhagen, Center Boulevard 5, Copenhagen, Denmark. Presentation Date(s): Jun-01-2022. Jun-02-2022.

Neutral

ChemoCentryx, Inc. Presents at The 2022 ASCO Annual Meeting, Jun-05-2022 08:00 AM

2022-05-31 20:05:00

ChemoCentryx, Inc. Presents at The 2022 ASCO Annual Meeting, Jun-05-2022 08:00 AM. Venue: McCormick Place, Chicago, Illinois, United States.

Negative

ChemoCentryx Announces Changes to its Board of Directors

2022-05-31 12:30:00

ChemoCentryx, Inc. announced changes to the composition of its Board of Directors. David E. Wheadon, M.D., has been elected to the Board as an independent director, and Henry A. McKinnell, Jr., Ph.D., is retiring from the Board, effective May 26, 2022. Dr. Wheadon retired from AstraZeneca PLC in 2019 as Senior Vice President, Global Regulatory Affairs, Patient Safety and Quality Assurance, a position he had held since 2014. Before joining AstraZeneca, Dr. Wheadon held a variety of leadership roles in the healthcare sector, including Executive Vice President, Research and Advocacy at the Juvenile Diabetes Research Foundation, Senior Vice President of Global Pharmaceutical Regulatory and Medical Sciences at Abbott Laboratories, and Senior Vice President of U.S. Regulatory Affairs at GlaxoSmithKline Laboratories. Dr. Wheadon has also served as Senior Vice President, Scientific and Regulatory Affairs at PhRMA, the Washington D.C.-based Pharmaceutical Industry Research and Manufacturers Association, during which time he interacted with the Food and Drug Administration (FDA), the Department of Health and Human Services (HHS), and the National Institutes of Health (NIH).Dr. Wheadon holds a M.D. from Johns Hopkins University School of Medicine and an A.B. in Biology from Harvard University. He completed his postdoctoral training in Psychiatry at Tufts/New England Medical Center in Boston, Massachusetts. He currently serves on the boards of Karuna Therapeutics Inc., Sotera Health Company, and Vaxart, Inc.

Neutral

ChemoCentryx, Inc. Presents at H.C. Wainwright Global Investment Conference 2022, May-24-2022 12:30 PM

2022-05-16 12:30:00

ChemoCentryx, Inc. Presents at H.C. Wainwright Global Investment Conference 2022, May-24-2022 12:30 PM. Venue: Fontainebleau Miami Beach Hotel, 4441 Collins Avenue, Miami Beach, Florida, United States. Speakers: Thomas J. Schall, Founder, President, CEO & Chairman.

Neutral

The International Society For Pharmacoeconomics And Outcomes Research Inc, ISPOR 2022, May 15, 2022 through May 18, 2022

2022-05-11 19:48:00

The International Society For Pharmacoeconomics And Outcomes Research Inc, ISPOR 2022, May 15, 2022 through May 18, 2022. Venue: Washington D.C., District Of Columbia, United States.

Neutral

ChemoCentryx, Inc. Presents at American Thoracic Society 2022 International Conference, May-17-2022 03:15 PM

2022-05-11 12:30:00

ChemoCentryx, Inc. Presents at American Thoracic Society 2022 International Conference, May-17-2022 03:15 PM. Venue: San Francicso, California, United States.

Neutral

ChemoCentryx, Inc. Presents at ISPOR 2022, May-17-2022 05:30 PM

2022-05-11 12:30:00

ChemoCentryx, Inc. Presents at ISPOR 2022, May-17-2022 05:30 PM. Venue: Washington D.C., District Of Columbia, United States.

Neutral

European Renal Association - European Dialisi and Transplant Association, 59thERA Conference (European Renal Association), May 19, 2022 through May 22, 2022

2022-05-11 12:30:00

European Renal Association - European Dialisi and Transplant Association, 59thERA Conference (European Renal Association), May 19, 2022 through May 22, 2022.

Neutral

ChemoCentryx, Inc. Presents at 59thERA Conference (European Renal Association), May-20-2022 05:00 PM

2022-05-11 12:30:00

ChemoCentryx, Inc. Presents at 59thERA Conference (European Renal Association), May-20-2022 05:00 PM.

Neutral

ChemoCentryx, Inc., Q1 2022 Earnings Call, May 05, 2022

2022-04-28 12:30:00

ChemoCentryx, Inc., Q1 2022 Earnings Call, May 05, 2022

Neutral

ChemoCentryx, Inc. to Report Q1, 2022 Results on May 05, 2022

2022-04-28 12:30:00

ChemoCentryx, Inc. announced that they will report Q1, 2022 results After-Market on May 05, 2022

Positive

ChemoCentryx, Inc. Reports Pharmacokinetic and Pharmacodynamic Results from Ongoing Phase I Trial of Orally Administered PD-L1 Inhibitor, Ccx559, At American Association for Cancer Research (Aacr) Annual Meeting 2022

2022-04-13 12:30:00

ChemoCentryx, Inc. announced the presentation of preclinical data and initial pharmacokinetic (PK) and pharmacodynamic data from the ongoing Phase I clinical study of CCX559 during a poster session at the American Association for Cancer Research Annual Meeting 2022. The PD-L1/PD-1 interaction is one of the major immune checkpoints that limits the ability of effector T cells to destroy cancer cells. As a potential next generation therapy, an orally administered small molecule inhibitor of PD-L1 could have advantageous properties compared to approved monoclonal antibodies, such as better penetration into solid tumors, reduced immunogenicity, lack of Fc-mediated side effects and convenience of oral administration. Preclinical characterization has demonstrated that CCX559 is a potent inhibitor of PD-L1 that blocks binding to PD-1 and CD80 and prevents PD-L1 inhibition of T cell activation. During 2021, ChemoCentryx initiated a first-in-human Phase I dose escalation study to evaluate the safety, tolerability, PK and PD of CCX559 in patients with various types of advanced cancer. In this Phase I basket study, CCX559 is taken orally once per day at specified dose levels, starting at 30 mg and ranging to date to 120 mg. In the AACR poster titled, CCX559, an orally administered small molecule PD-L1 inhibitor for the treatment of solid tumors: Initial Pharmacokinetic and Pharmacodynamic Results from the in Progress First-In-Human Trial, ChemoCentryx reported initial data available to date from patients enrolled in the first three dose cohorts in the ongoing Phase I study. Patients received CCX559 once daily at doses of 30 mg, 60 mg and 120 mg. All patients receiving 120 mg of CCX559 were included in the PK evaluation reported in the poster. PD data for seven of the 120 mg patients were also presented. PK evaluation shows human CCX559 exposure is in line with preclinical projections. The mean exposure at 120 mg CCX559 in patients is comparable to exposures with anti-tumor activity in preclinical models and sufficient for PD-L1 target coverage, the half-life of the drug was also in line with projections. PD activity results from the first cycle of treatment indicate that CCX559 is immunomodulatory. CD4 and CD8 T cell proliferation increased in all dose groups; soluble PD-L1 levels in plasma were significantly increased in the 120 mg patients by the end of the first cycle of dosing; and plasma IFN?, CXCL9, CXCL10 were increased in the majority of patients assessed at 120 mg. The PD activity of CCX559 is consistent with approved antibody inhibitors of PD-L1, in the extent and kinetics of the observed Th1 responses. ChemoCentryx expects to present additional findings from this ongoing Phase I study at major oncology conferences through 2022. During the second half of 2022, the Company plans to advance CCX559 into a Phase Ib/II clinical trial to measure anti-tumor effects of CCX559 more directly.

Neutral

ChemoCentryx, Inc., Annual General Meeting, May 26, 2022

2022-04-05 20:09:00

ChemoCentryx, Inc., Annual General Meeting, May 26, 2022, at 10:00 Pacific Daylight. Location: at the company’s headquarters, located at 835 Industrial Road, Suite 600, San Carlos California United States Agenda: To elect three directors to serve as Class II directors for a three-year term to expire at the 2025 annual meeting of stockholders; to consider and vote upon the ratification of the selection of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2022; to consider and vote upon, on an advisory basis, the compensation of named executive officers as disclosed in this proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission; and to transact such other business as may be properly brought before the meeting or any adjournment or postponement thereof.

Neutral

ChemoCentryx, Inc. Presents at Wells Fargo Annual Biotech Forum, Apr-12-2022

2022-03-29 20:00:00

ChemoCentryx, Inc. Presents at Wells Fargo Annual Biotech Forum, Apr-12-2022 . Venue: Miami, Florida, United States. Speakers: Susan M. Kanaya, Executive VP, Chief Financial & Administrative Officer, Secretary and Director, Thomas J. Schall, Founder, President, CEO & Chairman, William S. Slattery, Vice President of Investor Relations & Corporate Communications.

Neutral

Wells Fargo Securities, LLC, Wells Fargo Annual Biotech Forum, Apr 12, 2022 through Apr 13, 2022

2022-03-29 11:02:00

Wells Fargo Securities, LLC, Wells Fargo Annual Biotech Forum, Apr 12, 2022 through Apr 13, 2022. Venue: Miami, Florida, United States.

Neutral

H.C. Wainwright & Co., LLC, H.C. Wainwright Global Investment Conference 2022, May 23, 2022 through May 26, 2022

2022-02-28 18:21:00

H.C. Wainwright & Co., LLC, H.C. Wainwright Global Investment Conference 2022, May 23, 2022 through May 26, 2022. Venue: Fontainebleau Miami Beach Hotel, 4441 Collins Avenue, Miami Beach, Florida, United States.

Neutral

American Society Of Clinical Oncology, Inc., the 2022 ASCO Annual Meeting, Jun 03, 2022 through Jun 07, 2022

2021-12-10 06:32:00

American Society Of Clinical Oncology, Inc., The 2022 ASCO Annual Meeting, Jun 03, 2022 through Jun 07, 2022. Venue: McCormick Place, Chicago, Illinois, United States.

Neutral

ChemoCentryx, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference, Nov-29-2021

2021-11-22 15:06:00

ChemoCentryx, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference, Nov-29-2021 . Venue: New York, New York, United States.

Neutral

American Thoracic Society, Inc, American Thoracic Society 2022 International Conference, May 13, 2022 through May 18, 2022

2021-11-13 09:53:00

American Thoracic Society, Inc, American Thoracic Society 2022 International Conference, May 13, 2022 through May 18, 2022. Venue: San Francicso, California, United States.

Positive

ChemoCentryx, Inc Announces Positive Recommendation for Use of TAVNEOS™ (avacopan) in ANCA Vasculitis Adopted by European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP)

2021-11-12 13:30:00

ChemoCentryx, Inc. announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending marketing authorization for the Company’s TAVNEOS (avacopan), an orally administered selective complement 5a receptor inhibitor, in combination with a rituximab or cyclophosphamide regimen, indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA). Following the CHMP’s positive opinion, the European Commission will render an official decision as to the authorization of the use of TAVNEOS in the European Union in January 2022. Under the terms of the Company’s Kidney Health Alliance with Vifor Pharma, Vifor Pharma has exclusive rights to commercialize TAVNEOS in countries outside of the United States. Vifor Pharma has granted Kissei Pharmaceutical Co. Ltd. an exclusive license to commercialize TAVNEOS (avacopan), in Japan, where TAVNEOS was approved for use in ANCA vasculitis patients in September. Vifor Pharma will pay ChemoCentryx royalties in the teens to the mid-twenties percent on potential ex-US net sales off one aggregate net sales line. In the United States, TAVNEOS is indicated as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]) in combination with standard therapy including glucocorticoids. TAVNEOS does not eliminate glucocorticoid use.

Neutral

ChemoCentryx, Inc. Presents at Stifel 2021 Virtual Healthcare Conference, Nov-17-2021 02:00 PM

2021-11-10 13:00:00

ChemoCentryx, Inc. Presents at Stifel 2021 Virtual Healthcare Conference, Nov-17-2021 02:00 PM. Venue: New York, New York, United States. Speakers: Thomas J. Schall, Founder, President, CEO & Chairman.

Neutral

ChemoCentryx, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov-22-2021 10:00 AM

2021-11-10 13:00:00

ChemoCentryx, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov-22-2021 10:00 AM. Speakers: Thomas J. Schall, Founder, President, CEO & Chairman.

Neutral

ChemoCentryx, Inc., Q3 2021 Earnings Call, Nov 09, 2021

2021-11-02 14:04:00

ChemoCentryx, Inc., Q3 2021 Earnings Call, Nov 09, 2021

Neutral

ChemoCentryx, Inc. to Report Q3, 2021 Results on Nov 09, 2021

2021-11-02 14:04:00

ChemoCentryx, Inc. announced that they will report Q3, 2021 results After-Market on Nov 09, 2021

Neutral

SVB Leerink LLC, 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb 14, 2022 through Feb 18, 2022

2021-10-29 14:57:00

SVB Leerink LLC, 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb 14, 2022 through Feb 18, 2022. Venue: New York, New York, United States.

Neutral

Piper Sandler Companies, Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov 22, 2021

2021-10-25 10:00:00

Piper Sandler Companies, Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov 22, 2021.

Negative

Chemocentryx Appoints Rita I. Jain, M.D. as Executive Vice President, Chief Medical Officer

2021-10-11 12:30:00

ChemoCentryx, Inc. announced the appointment of Rita I. Jain, M.D., as Executive Vice President, Chief Medical Officer. In this role, she will oversee development activities including clinical development, development operations, regulatory affairs, and drug safety and pharmacovigilance. Dr. Jain will continue to serve on the ChemoCentryx board of directors as an executive employee director. Dr. Jain, a board-certified rheumatologist, brings more than 20 years of drug development experience leading multiple global programs across early and late stages of development. Dr Jain previously served as Chief Medical officer of Immunovant, Inc. and prior to that Senior Vice President and Chief Medical Officer of Akebia Therapeutics, Inc. Before joining Akebia, Dr. Jain was Vice President of Men's and Women's Health and Metabolic Development at AbbVie, Inc., and prior to that served in various leadership roles including Divisional Vice President at Abbott Laboratories. Dr. Jain led the design and execution of multiple late-stage programs, including for Orilissa® and Oriahnn®. She has also led programs across a diverse set of therapeutic areas including inflammation, pain, immunology and nephrology, among others. Before Abbott, she held management positions in the Arthritis, Inflammation and Pain Group at G.D. Searle. Earlier in her career, Dr. Jain was a faculty member at North Shore University Hospital in New York, with an academic appointment as Assistant Professor of Medicine, New York University School of Medicine. Dr. Jain received her B.S. in biology from LIU/C.W. Post and her M.D. from the State University of New York at Stony Brook School of Medicine. Dr. Jain completed her medical training in internal medicine at Staten Island University Hospital followed by a Fellowship in Rheumatology at North Shore University Hospital and a Clinical Research Fellowship at the University of Texas Southwestern Medical Center, Dallas.

Neutral

ChemoCentryx, Inc. - Special Call

2021-10-08 11:00:00

ChemoCentryx, Inc. - Special Call

Positive

ChemoCentryx, Inc. Announces FDA Approval of TAVNEOS™ (avacopan) in ANCA-Associated Vasculitis

2021-10-08 11:00:00

ChemoCentryx, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved TAVNEOS (avacopan), an orally administered selective complement 5a receptor inhibitor, as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (also known as ANCA-associated vasculitis or ANCA vasculitis), specifically granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) (the two main forms of ANCA vasculitis), in combination with standard therapy. ANCA-associated vasculitis is a systemic autoimmune disease in which over-activation of the complement system further activates neutrophils, leading to inflammation and eventual destruction of small blood vessels. This results in organ damage and failure, with the kidney as the major target, and is often fatal if not treated. TAVNEOS is the first FDA approved orally-administered inhibitor of the complement C5a receptor. The approval in ANCA-associated vasculitis was supported by the results of the pivotal Phase III ADVOCATE trial, which were highlighted in the February 2021 edition of The New England Journal of Medicine (NEJM). The ADVOCATE trial of TAVNEOS was a global, randomized, double-blind, active-controlled, double-dummy Phase III trial of 330 patients with ANCA-associated vasculitis in 20 countries. Eligible study subjects were randomized to receive either rituximab or cyclophosphamide (followed by azathioprine/mycophenolate) and either TAVNEOS (avacopan) or study-supplied oral prednisone. Subjects in both treatment groups could also receive non-protocol glucocorticoids if needed. The study met its primary endpoints of disease remission at 26 weeks and sustained remission at 52 weeks, as assessed by the Birmingham Vasculitis Activity Score, or BVAS. The study demonstrated superiority to a prednisone-based standard of care with respect to sustained remission at 52 weeks. The most common adverse reactions (=5% of patients and higher in the TAVNEOS group vs. prednisone group) were: nausea, headache, hypertension, diarrhea, vomiting, rash, fatigue, upper abdominal pain, dizziness, blood creatinine increase, and paresthesia.

Positive

ChemoCentryx Announces Approval in Japan of TAVNEOS™ (Avacopan) for the Treatment of ANCA-Associated Vasculitis

2021-09-27 12:30:00

ChemoCentryx, Inc. announced that Kissei Pharmaceutical Co. Ltd. has received approval from the Japanese Ministry of Health, Labor, and Welfare (MHLW) to market TAVNEOS™ (avacopan), an orally administered selective complement 5a receptor inhibitor, in Japan for the treatment of patients with microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA), the two main forms of anti-neutrophil cytoplasmic autoantibody-associated vasculitis also known as ANCA-associated vasculitis or ANCA vasculitis. ChemoCentryx'sKidney Health Alliance with Vifor Pharma provides Vifor Pharma with exclusive rights to commercialize avacopan in markets outside of the U.S., and Vifor Pharma has granted Kissei Pharmaceutical Co. Ltd. an exclusive license to commercialize TAVNEOS™ (avacopan), in Japan. ANCA-associated vasculitis was officially designated an intractable disease by the MHLW. Intractable diseases are rare diseases for which no effective treatment exists but for which long-term treatment is required. Japan promotes research related to intractable diseases and financially supports patients with these diseases.

Neutral

ChemoCentryx, Inc. Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-13-2021 07:00 AM

2021-09-02 12:33:00

ChemoCentryx, Inc. Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-13-2021 07:00 AM. Venue: Lotte New York Palace Hotel, New York City, New York, United States. Speakers: Thomas J. Schall, Founder, President, CEO & Chairman.

Neutral

ChemoCentryx, Inc. Presents at Citi’s 16th Annual BioPharma Virtual Conference, Sep-08-2021

2021-09-01 19:46:00

ChemoCentryx, Inc. Presents at Citi’s 16th Annual BioPharma Virtual Conference, Sep-08-2021 . Venue: New York, United States.

Neutral

ChemoCentryx, Inc. has filed a Shelf Registration in the amount of $13.87 million.

2021-08-10 00:00:00

ChemoCentryx, Inc. has filed a Shelf Registration in the amount of $13.87 million. Security Name: Common Stock Securities Offered: 950,000 Transaction Features: ESOP Related Offering

Neutral

ChemoCentryx, Inc. Presents at Canaccord Genuity 41st Annual Growth Conference, Aug-11-2021 05:00 PM

2021-08-04 12:30:00

ChemoCentryx, Inc. Presents at Canaccord Genuity 41st Annual Growth Conference, Aug-11-2021 05:00 PM. Speakers: Thomas J. Schall, Founder, President, CEO & Chairman.

Neutral

ChemoCentryx, Inc. to Report Q2, 2021 Results on Aug 09, 2021

2021-08-02 12:36:00

ChemoCentryx, Inc. announced that they will report Q2, 2021 results After-Market on Aug 09, 2021

Neutral

ChemoCentryx, Inc., Q2 2021 Earnings Call, Aug 09, 2021

2021-08-02 12:30:00

ChemoCentryx, Inc., Q2 2021 Earnings Call, Aug 09, 2021

Neutral

ChemoCentryx, Inc. Presents at Wells Fargo 2021 Virtual Healthcare Conference, Sep-09-2021 04:40 PM

2021-07-22 14:24:00

ChemoCentryx, Inc. Presents at Wells Fargo 2021 Virtual Healthcare Conference, Sep-09-2021 04:40 PM. Speakers: Susan M. Kanaya, Executive VP, Chief Financial & Administrative Officer, Secretary and Director, Tausif Butt, Executive VP & COO, Thomas J. Schall, Founder, President, CEO & Chairman.

Neutral

Wells Fargo Securities, LLC, Wells Fargo 2021 Virtual Healthcare Conference, Sep 09, 2021 through Sep 10, 2021

2021-07-22 09:08:00

Wells Fargo Securities, LLC, Wells Fargo 2021 Virtual Healthcare Conference, Sep 09, 2021 through Sep 10, 2021.

Neutral

Stifel, Nicolaus & Company, Incorporated, Stifel 2021 Virtual Healthcare Conference, Nov 15, 2021 through Nov 17, 2021

2021-07-08 08:44:00

Stifel, Nicolaus & Company, Incorporated, Stifel 2021 Virtual Healthcare Conference, Nov 15, 2021 through Nov 17, 2021. Venue: New York, New York, United States.

Positive

ChemoCentryx, Inc. Announces Filing of Amendment to NDA Submission and Extension of the PDUFA Review Period for Avacopan in the Treatment of Anca-Associated Vasculitis

2021-07-06 12:30:00

ChemoCentryx, Inc. announced that, following consultations with the U.S. Food and Drug Administration (FDA), it filed an amendment to its New Drug Application (NDA) for avacopan for the treatment of Anti-neutrophil Cytoplasmic Autoantibody (ANCA)-associated vasculitis, addressing points raised during the FDA Advisory Committee meeting on May 6, 2021. The FDA has indicated that the filing constitutes a major amendment to the NDA and will result in the setting of a new PDUFA goal date of October 7, 2021. The NDA is primarily based on data from the Phase III ADVOCATE trial of avacopan for the treatment of ANCA-associated vasculitis. On May 6, the FDA’s Arthritis Advisory Committee voted 9-9 on whether the efficacy data support approval of avacopan, 10-8 that the safety profile of avacopan is adequate to support approval, and 10-8 that the benefit-risk profile is adequate to support approval of avacopan at the proposed dose of 30 mg twice daily. The Marketing Authorization Application (MAA) for avacopan in the treatment of ANCA-associated vasculitis was validated by the European Medicines Agency (EMA) in November 2020, and the Japanese New Drug Application was accepted for review by the Japanese Pharmaceuticals and Medical Device Agency in February 2021.

Negative

Rosen Law Firm Encourages ChemoCentryx, Inc. Investors with Losses to Secure Counsel Before Important July 6, 2021 Deadline in Securities Class Action

2021-07-04 15:15:00

Rosen Law Firm reminded purchasers of the securities of ChemoCentryx, Inc. between November 26, 2019 and May 6, 2021, inclusive (the “Class Period”), of the important July 6, 2021 lead plaintiff deadline. If Investors purchased ChemoCentryx securities during the Class Period Investors may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. A class action lawsuit has already been filed. If Investors wish to serve as lead plaintiff, Investors must move the Court no later than July 6, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. According to the lawsuits, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) the study design of the Phase III ADVOCATE trial presented issues about the interpretability of the trial data to define a clinically meaningful benefit of avacopan and its role in the management of ANCA-associated vasculitis; (2) the data from the Phase III ADVOCATE trial raised serious safety concerns for avacopan; (3) these issues presented a substantial concern regarding the viability of ChemoCentryx’s New Drug Application (“NDA”) for avacopan for the treatment of ANCA-associated vasculitis; and (4) as a result of the foregoing, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

Fundamental Summary

Looking at ChemoCentryx's financials of Q1 reflected decent results. We do believe, though, that macro-related market conditions will influence their performance more significantly than its individual results. Therefore, ChemoCentryx received an overall score of 71, translating into a HOLD ranking.

ChemoCentryx reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported revenue was USD 5.46 million compared to USD 10.35 million a year ago. Net loss was USD 38.61 million compared to USD 29.71 million a year ago. Basic loss per share from continuing operations was USD 0.55 compared to USD 0.43 a year ago.

Business Description

ChemoCentryx, a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx was incorporated in 1996 and is headquartered in San Carlos, California.

Sector Overview

ChemoCentryx is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. ChemoCentryx's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.

Fundamental Highlights


Parameter Value Change Score
Assets 440.5 3.5% 77
Liabilities 181.7 30.2% 72
Price to Book 6.9 -23.1% 52
Cash & Equivalents 40.6 -18.8% 53
Equity 258.7 -9.6% 47
EBITDA -128.9 -6.9% 57
Total Revenues 27.3 -15.2% 97
Parameter Value Change Score
Return on Equity -45.4 -15.7% 71
Net Cashflow -28.0 -258.2% 84
Capital Expenditure -8.4 56.0% 97
Asset Turnover 0.1 -14.7% 50
Free Cashflow -0.8 43.6% 92

* All values are TTM

The below chart reflects ChemoCentryx's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While ChemoCentryx's peer average final assessment score stands on 61.0, ChemoCentryx's score is 71.

  •  CCXI
  •  Peers average
Name Market Cap Balance Sheet Income Statement Cash Flow Rating Final Assessment mc_sort Hidden
Amgen Inc. 130.1B 69 78 81
Hold
77
77 0 1
Gilead Sciences, Inc. 78.0B 57 73 62
Underperform
60
60 1 1
Vertex Pharmaceuticals Incorporated 70.6B 78 75 71
Buy
79
79 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 73
Hold
72
72 3 1
BioNTech SE 34.0B 75 79 72
Buy
79
79 4 1
Seagen Inc. 32.9B 61 62 58
Underperform
57
57 5 1
Biogen Inc. 29.7B 76 70 66
Hold
74
74 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 54 80 85
Hold
69
69 7 1
Incyte Corporation 16.8B 83 73 84
Buy
86
86 8 1
BioMarin Pharmaceutical Inc. 15.4B 70 82 63
Hold
74
74 9 1
United Therapeutics Corporation 10.6B 76 82 93
Strong Buy
88
88 10 1
Neurocrine Biosciences, Inc. 9.3B 68 55 63
Underperform
60
60 11 1
Exelixis, Inc. 6.7B 70 81 87
Buy
81
81 12 1
Sarepta Therapeutics, Inc. 6.5B 58 78 93
Hold
73
73 13 1
Halozyme Therapeutics, Inc. 6.3B 74 82 75
Buy
81
81 14 1
Ionis Pharmaceuticals, Inc. 5.4B 62 86 89
Buy
79
79 15 1
Ascendis Pharma A/S 5.2B 68 54 62
Underperform
60
60 16 1
Alkermes plc 5.0B 62 62 92
Hold
69
69 17 1
Cytokinetics, Incorporated 4.1B 64 66 69
Hold
65
65 18 1
Novavax, Inc. 4.0B 77 75 60
Hold
74
74 19 1
Mirati Therapeutics, Inc. 3.8B 50 64 65
Underperform
52
52 20 1
Natera, Inc. 3.6B 54 52 58
Underperform
47
47 21 1
Arrowhead Pharmaceuticals, Inc. 3.4B 71 76 70
Hold
74
74 22 1
PTC Therapeutics, Inc. 2.8B 51 73 72
Underperform
59
59 23 1
Insmed Incorporated 2.4B 55 57 82
Underperform
58
58 24 1
ACADIA Pharmaceuticals Inc. 2.3B 63 58 72
Hold
61
61 25 1
BioCryst Pharmaceuticals, Inc. 1.9B 55 66 67
Underperform
57
57 26 1
Ironwood Pharmaceuticals, Inc. 1.8B 68 79 78
Hold
76
76 27 1
Myriad Genetics, Inc. 1.5B 52 96 59
Hold
66
66 28 1
Agios Pharmaceuticals, Inc. 1.2B 50 75 75
Hold
60
60 29 1
IVERIC bio, Inc. 1.1B 50 70 64
Underperform
54
54 30 1
FibroGen, Inc. 1.0B 73 67 84
Hold
76
76 31 1
Syndax Pharmaceuticals, Inc. 1.0B 58 62 57
Underperform
54
54 32 1
ImmunoGen, Inc. 946.1M 56 64 87
Hold
64
64 33 1
Enanta Pharmaceuticals, Inc. 922.8M 60 75 66
Hold
65
65 34 1
Deciphera Pharmaceuticals, Inc. 914.0M 61 77 94
Hold
75
75 35 1
Anavex Life Sciences Corp. 767.1M 61 75 72
Hold
67
67 36 1
Sangamo Therapeutics, Inc. 600.0M 48 76 91
Hold
65
65 37 1
AnaptysBio, Inc. 586.3M 52 68 80
Hold
60
60 38 1
Geron Corporation 566.2M 60 78 77
Hold
70
70 39 1
Mersana Therapeutics, Inc. 449.1M 58 47 65
Underperform
50
50 40 1
Inovio Pharmaceuticals, Inc. 416.9M 46 72 71
Underperform
54
54 41 1
Arbutus Biopharma Corporation 388.2M 60 67 95
Hold
71
71 42 1
Intercept Pharmaceuticals, Inc. 386.3M 57 86 96
Hold
78
78 43 1
Anika Therapeutics, Inc. 322.7M 64 77 63
Hold
73
73 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 51 69 77
Hold
61
61 45 1
Precigen, Inc. 299.1M 73 79 74
Buy
79
79 46 1
bluebird bio, Inc. 288.7M 50 96 83
Hold
78
78 47 1
Rigel Pharmaceuticals, Inc. 187.5M 62 64 41
Underperform
52
52 48 1
MacroGenics, Inc. 184.6M 47 71 65
Underperform
53
53 49 1
Exact Sciences Corporation 7.2B 47 62 56
Underperform
46
46 50 1
Amicus Therapeutics, Inc. 3.0B 56 58 85
Hold
61
61 51 1
CureVac N.V. 2.6B 57 74 90
Hold
70
70 52 1
Fate Therapeutics, Inc. 2.4B 53 46 61
Underperform
45
45 53 1
Abgenix Inc. 2.1B 67 47 58
Underperform
45
45 54 1
Xenon Pharmaceuticals Inc. 1.9B 61 56 89
Hold
64
64 55 1
Iovance Biotherapeutics, Inc. 1.7B 63 71 77
Hold
68
68 56 1
Xencor, Inc. 1.6B 67 79 98
Buy
82
82 57 1
Emergent BioSolutions Inc. 1.6B 61 66 75
Hold
65
65 58 1
Dynavax Technologies Corporation 1.5B 63 67 68
Hold
64
64 59 1
Ligand Pharmaceuticals Incorporated 1.5B 56 69 84
Hold
65
65 60 1
Aurinia Pharmaceuticals Inc. 1.4B 52 70 84
Hold
62
62 61 1
Veracyte, Inc. 1.4B 57 55 82
Underperform
59
59 62 1
Sierra Oncology, Inc. 1.3B 80 61 52
Hold
68
68 63 1
Celldex Therapeutics, Inc. 1.3B 57 70 69
Hold
61
61 64 1
CareDx, Inc 1.2B 52 50 86
Underperform
54
54 65 1
Vericel Corporation 1.1B 57 56 65
Underperform
53
53 66 1
Avid Bioservices, Inc. 959.5M 67 75 66
Hold
69
69 67 1
MannKind Corporation 957.2M 57 61 66
Underperform
56
56 68 1
Merus N.V. 941.6M 70 54 71
Hold
64
64 69 1
Sorrento Therapeutics, Inc. 747.5M 74 55 52
Hold
61
61 70 1
Amarin Corporation plc 734.5M 55 63 55
Underperform
52
52 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 75 77 87
Buy
84
84 72 1
Northwest Biotherapeutics, Inc. 682.9M 65 79 85
Hold
77
77 73 1
Organogenesis Holdings Inc. 612.1M 60 69 75
Hold
64
64 74 1
CTI BioPharma Corp. 603.6M 54 59 56
Underperform
50
50 75 1
Vanda Pharmaceuticals Inc. 598.8M 64 62 69
Hold
62
62 76 1
Eagle Pharmaceuticals, Inc. 546.4M 75 78 73
Buy
79
79 77 1
Immatics N.V. 538.7M 76 77 86
Buy
84
84 78 1
Agenus Inc. 520.5M 54 74 58
Underperform
57
57 79 1
Radius Health, Inc. 499.8M 54 82 57
Hold
61
61 80 1
Vaxart, Inc. 440.0M 53 68 65
Underperform
56
56 81 1
Affimed N.V. 415.0M 54 66 74
Underperform
59
59 82 1
ADMA Biologics, Inc. 396.6M 68 57 71
Hold
64
64 83 1
MiMedx Group, Inc. 391.5M 45 59 60
Underperform
45
45 84 1
Albireo Pharma, Inc. 362.9M 54 65 63
Underperform
55
55 85 1
AVEO Pharmaceuticals, Inc. 337.5M 66 74 95
Hold
78
78 86 1
Zymeworks Inc. 324.7M 62 56 57
Underperform
54
54 87 1
Heron Therapeutics, Inc. 314.6M 58 62 71
Underperform
59
59 88 1
Silence Therapeutics plc 313.4M 66 72 69
Hold
70
70 89 1
AC Immune SA 299.8M 68 70 68
Hold
68
68 90 1
Viridian Therapeutics, Inc. 293.2M 65 53 65
Underperform
56
56 91 1
Sutro Biopharma, Inc. 245.5M 61 56 74
Underperform
59
59 92 1
Chimerix, Inc. 178.4M 49 65 83
Underperform
58
58 93 1
DermTech, Inc. 165.3M 56 52 58
Underperform
47
47 94 1
Gelesis Holdings, Inc. 111.5M 78 39 80
Hold
66
66 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 49 61 58
Underperform
56
56 96 1
INSYS Therapeutics, Inc. 3.2M 43 70 73
Underperform
55
55 97 1

Technical Analysis

When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. ChemoCentryx's stock is now priced above its 50-day, but below its 5-day and 200-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is strengthening. Historically, this is a positive setup in the medium-term. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), ChemoCentryx's stock doesn't strongly signal being overbought or oversold. Overall, these technical indicators signal negative momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 57.

Bearish 57
Close Price 25.08
52W Low 13.18
52W High 40.5
5D MA 26.19
50D MA 21.62
200D MA 27.74
MACD 1.15
RSI 40.11
STOCH 43.62

Balance Sheet Analysis

ChemoCentryx appears likely to maintain its strong balance sheet metrics and momentum going forward. ChemoCentryx assets on their balance sheet, moved to 440.5, which is a 3.5% change from the last period. This growth should support upward pressure on its's stock price, which better captures their intrinsic value. Consequently, their asset movement received a grade of 77. Also, ChemoCentryx is doing a good job of keeping its liabilities under control and growing intelligently. At filing, their liabilities were 181.7, representing 30.2% change from the previous period. These numbers show that management has successfully encouraged growth while managing liabilities, especially relative to their peers. These results statistically lead to positive movement in stock prices, so we rated its liabilities movement component 72. That said, one metric, Equity, stood out as particularly concerning. ChemoCentryx management produced disappointing equity metrics this period, which stood at 258.7, representing a -9.6% change. This parameter often affects companies in the same industry and market capitalization by up to 7.3%. This performance is significantly less impressive than its peers and competitors. Consequently, their equity movement received a grade of 47. Consequently, their balance sheet earned a rank of 61.

Parameter Value Change Score
Assets 440.5 3.5% 77
Liabilities 181.7 30.2% 72
Price to Book 6.9 -23.1% 52
Cash & Equivalents 40.6 -18.8% 53
Equity 258.7 -9.6% 47
* All values are TTM

The below chart describes ChemoCentryx's performance as reflected on its balance sheet with respect to its peers. While ChemoCentryx received a balance sheet score of 61, the average of its peers stands on 61.0.

  •  CCXI
  •  Peers average
Name Market Cap Liabilities Movement Asset Change Equity/Intangibles Adjustments Cash & Equivalents Book Value Momentum Balance Sheet mc_sort Hidden
Amgen Inc. 130.1B 72 68 86 53 62 69 0 1
Gilead Sciences, Inc. 78.0B 48 63 61 52 62 57 1 1
Vertex Pharmaceuticals Incorporated 70.6B 69 69 58 84 92 78 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 48 65 52 86 81 67 3 1
BioNTech SE 34.0B 75 69 64 97 73 75 4 1
Seagen Inc. 32.9B 59 68 55 43 66 61 5 1
Biogen Inc. 29.7B 57 72 92 50 76 76 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 50 66 46 44 61 54 7 1
Incyte Corporation 16.8B 71 72 95 82 79 83 8 1
BioMarin Pharmaceutical Inc. 15.4B 55 75 54 77 74 70 9 1
United Therapeutics Corporation 10.6B 61 74 58 60 88 76 10 1
Neurocrine Biosciences, Inc. 9.3B 67 69 55 51 78 68 11 1
Exelixis, Inc. 6.7B 53 66 57 84 81 70 12 1
Sarepta Therapeutics, Inc. 6.5B 68 69 49 41 58 58 13 1
Halozyme Therapeutics, Inc. 6.3B 59 68 65 72 85 74 14 1
Ionis Pharmaceuticals, Inc. 5.4B 59 68 58 43 67 62 15 1
Ascendis Pharma A/S 5.2B 51 70 85 94 54 68 16 1
Alkermes plc 5.0B 63 66 46 54 71 62 17 1
Cytokinetics, Incorporated 4.1B 49 79 42 76 62 64 18 1
Novavax, Inc. 4.0B 61 67 52 77 99 77 19 1
Mirati Therapeutics, Inc. 3.8B 53 66 57 48 42 50 20 1
Natera, Inc. 3.6B 73 65 43 95 42 54 21 1
Arrowhead Pharmaceuticals, Inc. 3.4B 72 71 63 65 73 71 22 1
PTC Therapeutics, Inc. 2.8B 57 61 80 49 37 51 23 1
Insmed Incorporated 2.4B 49 65 45 46 63 55 24 1
ACADIA Pharmaceuticals Inc. 2.3B 83 65 55 91 55 63 25 1
BioCryst Pharmaceuticals, Inc. 1.9B 46 67 46 50 62 55 26 1
Ironwood Pharmaceuticals, Inc. 1.8B 49 68 87 67 63 68 27 1
Myriad Genetics, Inc. 1.5B 51 62 51 43 57 52 28 1
Agios Pharmaceuticals, Inc. 1.2B 50 66 52 38 48 50 29 1
IVERIC bio, Inc. 1.1B 50 67 46 48 48 50 30 1
FibroGen, Inc. 1.0B 79 87 49 82 56 73 31 1
Syndax Pharmaceuticals, Inc. 1.0B 85 68 41 55 55 58 32 1
ImmunoGen, Inc. 946.1M 52 67 64 61 48 56 33 1
Enanta Pharmaceuticals, Inc. 922.8M 51 86 45 38 49 60 34 1
Deciphera Pharmaceuticals, Inc. 914.0M 56 71 38 82 63 61 35 1
Anavex Life Sciences Corp. 767.1M 50 67 50 75 66 61 36 1
Sangamo Therapeutics, Inc. 600.0M 59 64 47 45 46 48 37 1
AnaptysBio, Inc. 586.3M 85 63 41 37 51 52 38 1
Geron Corporation 566.2M 69 72 37 59 62 60 39 1
Mersana Therapeutics, Inc. 449.1M 75 68 39 82 52 58 40 1
Inovio Pharmaceuticals, Inc. 416.9M 56 66 38 54 40 46 41 1
Arbutus Biopharma Corporation 388.2M 86 65 61 48 55 60 42 1
Intercept Pharmaceuticals, Inc. 386.3M 46 68 57 41 61 57 43 1
Anika Therapeutics, Inc. 322.7M 76 68 63 64 65 64 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 48 68 51 43 51 51 45 1
Precigen, Inc. 299.1M 81 85 61 72 48 73 46 1
bluebird bio, Inc. 288.7M 48 67 42 38 57 50 47 1
Rigel Pharmaceuticals, Inc. 187.5M 53 67 51 90 63 62 48 1
MacroGenics, Inc. 184.6M 53 64 61 37 39 47 49 1
Exact Sciences Corporation 7.2B 57 58 45 42 52 47 50 1
Amicus Therapeutics, Inc. 3.0B 52 64 58 66 56 56 51 1
CureVac N.V. 2.6B 49 64 75 52 52 57 52 1
Fate Therapeutics, Inc. 2.4B 63 70 54 39 45 53 53 1
Abgenix Inc. 2.1B 81 57 86 92 45 67 54 1
Xenon Pharmaceuticals Inc. 1.9B 48 69 53 45 70 61 55 1
Iovance Biotherapeutics, Inc. 1.7B 52 74 72 87 45 63 56 1
Xencor, Inc. 1.6B 53 78 60 40 67 67 57 1
Emergent BioSolutions Inc. 1.6B 48 62 87 48 61 61 58 1
Dynavax Technologies Corporation 1.5B 52 69 54 38 76 63 59 1
Ligand Pharmaceuticals Incorporated 1.5B 75 63 61 49 52 56 60 1
Aurinia Pharmaceuticals Inc. 1.4B 51 67 59 41 47 52 61 1
Veracyte, Inc. 1.4B 64 68 54 66 51 57 62 1
Sierra Oncology, Inc. 1.3B 62 71 52 97 97 80 63 1
Celldex Therapeutics, Inc. 1.3B 48 69 61 44 57 57 64 1
CareDx, Inc 1.2B 54 67 52 39 51 52 65 1
Vericel Corporation 1.1B 51 65 56 53 61 57 66 1
Avid Bioservices, Inc. 959.5M 75 61 61 58 72 67 67 1
MannKind Corporation 957.2M 79 59 50 40 64 57 68 1
Merus N.V. 941.6M 59 68 50 83 81 70 69 1
Sorrento Therapeutics, Inc. 747.5M 89 71 50 97 73 74 70 1
Amarin Corporation plc 734.5M 51 65 58 72 51 55 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 52 69 70 77 86 75 72 1
Northwest Biotherapeutics, Inc. 682.9M 65 63 48 38 86 65 73 1
Organogenesis Holdings Inc. 612.1M 59 66 56 66 60 60 74 1
CTI BioPharma Corp. 603.6M 84 70 37 92 37 54 75 1
Vanda Pharmaceuticals Inc. 598.8M 82 70 47 89 56 64 76 1
Eagle Pharmaceuticals, Inc. 546.4M 83 70 73 46 79 75 77 1
Immatics N.V. 538.7M 56 70 84 95 73 76 78 1
Agenus Inc. 520.5M 73 62 37 55 60 54 79 1
Radius Health, Inc. 499.8M 50 64 50 44 59 54 80 1
Vaxart, Inc. 440.0M 69 67 47 56 47 53 81 1
Affimed N.V. 415.0M 56 66 63 56 47 54 82 1
ADMA Biologics, Inc. 396.6M 74 68 49 77 72 68 83 1
MiMedx Group, Inc. 391.5M 53 66 42 57 37 45 84 1
Albireo Pharma, Inc. 362.9M 48 65 42 58 62 54 85 1
AVEO Pharmaceuticals, Inc. 337.5M 76 68 61 78 60 66 86 1
Zymeworks Inc. 324.7M 77 69 70 90 43 62 87 1
Heron Therapeutics, Inc. 314.6M 84 65 48 43 58 58 88 1
Silence Therapeutics plc 313.4M 58 71 69 63 59 66 89 1
AC Immune SA 299.8M 84 64 47 53 75 68 90 1
Viridian Therapeutics, Inc. 293.2M 56 72 44 37 76 65 91 1
Sutro Biopharma, Inc. 245.5M 82 69 56 66 49 61 92 1
Chimerix, Inc. 178.4M 48 63 46 95 40 49 93 1
DermTech, Inc. 165.3M 76 72 51 52 43 56 94 1
Gelesis Holdings, Inc. 111.5M 47 76 48 76 98 78 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 37 71 45 39 55 49 96 1
INSYS Therapeutics, Inc. 3.2M 48 70 44 90 37 43 97 1

Income Statement Analysis

Overall, ChemoCentryx's critical income statement metrics appear to signal strong support and a high likelihood of positive growth going forward. ChemoCentryx reported highly encouraging numbers for its revenue efficiency. This characteristic can affect companies in the same industry and market capitalization by up to 13.1%. Their industry-leading revenue efficiency makes a strong case for upward pressure on its's stock price. As a result, its revenue efficiency earned a score of 97. Also, In this filing, ChemoCentryx reported a return on equity (ROE) ratio of -45.4, which represents a change of -15.7%. Its return factor metrics are even more remarkable when compared to their peers. Therefore, its return factors component earned a score of 71. On the other hand, EBITDA, jumped out as looking problematic. ChemoCentryx reported concerning EBITDA this period. At filing, EBITDA was reported as -128.9, representing -6.9% change from the previous period. This parameter coud affect companies in the same industry and market capitalization by up to 24.4%. The company's EBITDA metrics highlight a difficult overall financial situation, which may, unfortunately, continue moving forward unless management makes significant changes. Discouraging results like these statistically lead to negative pressure in stock prices, so we rated their EBITDA a grade of 57. Its income statement, therefore, earned a score of 73.

Parameter Value Change Score
EBITDA -128.9 -6.9% 57
Total Revenues 27.3 -15.2% 97
Return on Equity -45.4 -15.7% 71
* All values are TTM

The below chart describes ChemoCentryx's performance as reflected on its income statement with respect to its peers. While ChemoCentryx received a income statement score of 73 , the average of its peers stands on 64.0.

  •  CCXI
  •  Peers average
Name Market Cap Revenue Momentum Earning Movement Return Factors Momentum Income Statement mc_sort Hidden
Amgen Inc. 130.1B 74 75 64 78 0 1
Gilead Sciences, Inc. 78.0B 78 71 52 73 1 1
Vertex Pharmaceuticals Incorporated 70.6B 57 80 62 75 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 66 74 3 1
BioNTech SE 34.0B 41 89 75 79 4 1
Seagen Inc. 32.9B 54 65 70 62 5 1
Biogen Inc. 29.7B 90 57 73 70 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 60 86 56 80 7 1
Incyte Corporation 16.8B 59 77 60 73 8 1
BioMarin Pharmaceutical Inc. 15.4B 72 81 65 82 9 1
United Therapeutics Corporation 10.6B 57 91 54 82 10 1
Neurocrine Biosciences, Inc. 9.3B 53 54 77 55 11 1
Exelixis, Inc. 6.7B 54 91 54 81 12 1
Sarepta Therapeutics, Inc. 6.5B 49 89 55 78 13 1
Halozyme Therapeutics, Inc. 6.3B 53 84 85 82 14 1
Ionis Pharmaceuticals, Inc. 5.4B 62 94 53 86 15 1
Ascendis Pharma A/S 5.2B 38 68 46 54 16 1
Alkermes plc 5.0B 69 55 81 62 17 1
Cytokinetics, Incorporated 4.1B 95 50 73 66 18 1
Novavax, Inc. 4.0B 41 89 54 75 19 1
Mirati Therapeutics, Inc. 3.8B 76 55 78 64 20 1
Natera, Inc. 3.6B 52 51 78 52 21 1
Arrowhead Pharmaceuticals, Inc. 3.4B 38 92 53 76 22 1
PTC Therapeutics, Inc. 2.8B 54 78 66 73 23 1
Insmed Incorporated 2.4B 51 58 73 57 24 1
ACADIA Pharmaceuticals Inc. 2.3B 72 49 80 58 25 1
BioCryst Pharmaceuticals, Inc. 1.9B 41 74 72 66 26 1
Ironwood Pharmaceuticals, Inc. 1.8B 70 79 61 79 27 1
Myriad Genetics, Inc. 1.5B 89 93 57 96 28 1
Agios Pharmaceuticals, Inc. 1.2B 99 64 54 75 29 1
IVERIC bio, Inc. 1.1B 84 58 79 70 30 1
FibroGen, Inc. 1.0B 48 74 63 67 31 1
Syndax Pharmaceuticals, Inc. 1.0B 87 47 81 62 32 1
ImmunoGen, Inc. 946.1M 40 73 71 64 33 1
Enanta Pharmaceuticals, Inc. 922.8M 90 63 72 75 34 1
Deciphera Pharmaceuticals, Inc. 914.0M 60 79 70 77 35 1
Anavex Life Sciences Corp. 767.1M 84 69 60 75 36 1
Sangamo Therapeutics, Inc. 600.0M 72 72 73 76 37 1
AnaptysBio, Inc. 586.3M 97 50 77 68 38 1
Geron Corporation 566.2M 89 67 73 78 39 1
Mersana Therapeutics, Inc. 449.1M 37 54 72 47 40 1
Inovio Pharmaceuticals, Inc. 416.9M 96 57 68 72 41 1
Arbutus Biopharma Corporation 388.2M 37 82 53 67 42 1
Intercept Pharmaceuticals, Inc. 386.3M 71 93 40 86 43 1
Anika Therapeutics, Inc. 322.7M 63 80 62 77 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 98 48 82 69 45 1
Precigen, Inc. 299.1M 57 87 59 79 46 1
bluebird bio, Inc. 288.7M 99 91 61 96 47 1
Rigel Pharmaceuticals, Inc. 187.5M 99 44 82 64 48 1
MacroGenics, Inc. 184.6M 95 56 74 71 49 1
Exact Sciences Corporation 7.2B 57 67 54 62 50 1
Amicus Therapeutics, Inc. 3.0B 61 55 77 58 51 1
CureVac N.V. 2.6B 45 83 71 74 52 1
Fate Therapeutics, Inc. 2.4B 45 52 61 46 53 1
Abgenix Inc. 2.1B 47 47 47 47 54 1
Xenon Pharmaceuticals Inc. 1.9B 41 65 59 56 55 1
Iovance Biotherapeutics, Inc. 1.7B 84 60 75 71 56 1
Xencor, Inc. 1.6B 42 94 52 79 57 1
Emergent BioSolutions Inc. 1.6B 91 51 77 66 58 1
Dynavax Technologies Corporation 1.5B 51 69 77 67 59 1
Ligand Pharmaceuticals Incorporated 1.5B 92 53 78 69 60 1
Aurinia Pharmaceuticals Inc. 1.4B 38 81 68 70 61 1
Veracyte, Inc. 1.4B 45 63 57 55 62 1
Sierra Oncology, Inc. 1.3B 84 54 54 61 63 1
Celldex Therapeutics, Inc. 1.3B 96 53 78 70 64 1
CareDx, Inc 1.2B 61 44 82 50 65 1
Vericel Corporation 1.1B 76 44 82 56 66 1
Avid Bioservices, Inc. 959.5M 49 82 69 75 67 1
MannKind Corporation 957.2M 95 48 56 61 68 1
Merus N.V. 941.6M 48 60 59 54 69 1
Sorrento Therapeutics, Inc. 747.5M 50 60 60 55 70 1
Amarin Corporation plc 734.5M 95 44 82 63 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 48 88 58 77 72 1
Northwest Biotherapeutics, Inc. 682.9M 43 90 65 79 73 1
Organogenesis Holdings Inc. 612.1M 89 55 79 69 74 1
CTI BioPharma Corp. 603.6M 84 50 62 59 75 1
Vanda Pharmaceuticals Inc. 598.8M 89 46 81 62 76 1
Eagle Pharmaceuticals, Inc. 546.4M 39 94 53 78 77 1
Immatics N.V. 538.7M 37 93 53 77 78 1
Agenus Inc. 520.5M 57 83 45 74 79 1
Radius Health, Inc. 499.8M 94 71 68 82 80 1
Vaxart, Inc. 440.0M 99 51 72 68 81 1
Affimed N.V. 415.0M 95 49 75 66 82 1
ADMA Biologics, Inc. 396.6M 43 65 62 57 83 1
MiMedx Group, Inc. 391.5M 87 43 83 59 84 1
Albireo Pharma, Inc. 362.9M 46 69 77 65 85 1
AVEO Pharmaceuticals, Inc. 337.5M 38 89 54 74 86 1
Zymeworks Inc. 324.7M 58 53 77 56 87 1
Heron Therapeutics, Inc. 314.6M 61 60 75 62 88 1
Silence Therapeutics plc 313.4M 83 64 69 72 89 1
AC Immune SA 299.8M 83 61 65 70 90 1
Viridian Therapeutics, Inc. 293.2M 55 50 63 53 91 1
Sutro Biopharma, Inc. 245.5M 60 47 80 56 92 1
Chimerix, Inc. 178.4M 99 50 62 65 93 1
DermTech, Inc. 165.3M 49 48 78 52 94 1
Gelesis Holdings, Inc. 111.5M 41 46 56 39 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 83 49 92 61 96 1
INSYS Therapeutics, Inc. 3.2M 97 48 63 70 97 1

Cash Flow Analysis

Two metrics jump up as the most significant positive drivers of the cash flow's strength in ChemoCentryx's recent report: Capex and Free Cash flow. ChemoCentryx's management did a great job this period managing its capital expenditure (CapEx). In terms of the raw numbers, CapEx was reported as -8.4, which represents a 56.0% change from the last period. This remarkable CapEx growth is expected to reinforce upward momentum for its's stock price going forward. Consequently, their CapEx movement received a grade of 97. Also, Free cash flow numbers published by ChemoCentryx were -0.8, which was a 43.6% change from the previous filing. Companies in the same industry and market capitalization are typically affected by this parameter by up to 2.6%. These free cash flow numbers show that management has executed well while generating cash flow and encouraging growth. The company's free cash flow movement, therefore, received a grade of 92. On the other hand, Asset Turnover, jumped out as looking rather underwhelming. ChemoCentryx's asset turnover numbers were discouraging, reflecting significant concerns related to management's ability to leverage assets to generate sales effectively and efficiently. ChemoCentryx recorded asset turnover of 0.1, which represents a -14.7% change from the previous report. Companies in the same industry and market capitalization are typically affected by this parameter by up to 4.1%. Their asset turnover numbers are significantly less impressive when compared to their peers and competitors. Correspondingly, their asset turnover movement received a grade of 50. Therefore, we scored their cash flow a 87.

Parameter Value Change Score
Net Cashflow -28.0 -258.2% 84
Capital Expenditure -8.4 56.0% 97
Asset Turnover 0.1 -14.7% 50
Free Cashflow -0.8 43.6% 92
* All values are TTM

The below chart describes ChemoCentryx's performance as reflected on its cash flow with respect to its peers. While ChemoCentryx received a cash flow score of 87, the average of its peers stands on 69.0.

  •  CCXI
  •  Peers average
Name Market Cap Cashflow Momentum Free Cashflow Growth Capital Expenditure Growth Assets Factors Momentum Cash Flow mc_sort Hidden
Amgen Inc. 130.1B 80 74 67 74 81 0 1
Gilead Sciences, Inc. 78.0B 57 61 53 85 62 1 1
Vertex Pharmaceuticals Incorporated 70.6B 64 75 80 71 71 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 69 86 64 66 73 3 1
BioNTech SE 34.0B 73 97 50 52 72 4 1
Seagen Inc. 32.9B 53 53 50 87 58 5 1
Biogen Inc. 29.7B 58 54 90 73 66 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 82 80 70 89 85 7 1
Incyte Corporation 16.8B 78 79 92 74 84 8 1
BioMarin Pharmaceutical Inc. 15.4B 59 48 66 77 63 9 1
United Therapeutics Corporation 10.6B 93 92 68 80 93 10 1
Neurocrine Biosciences, Inc. 9.3B 63 43 54 74 63 11 1
Exelixis, Inc. 6.7B 79 90 89 83 87 12 1
Sarepta Therapeutics, Inc. 6.5B 85 89 95 87 93 13 1
Halozyme Therapeutics, Inc. 6.3B 83 66 52 49 75 14 1
Ionis Pharmaceuticals, Inc. 5.4B 88 96 60 86 89 15 1
Ascendis Pharma A/S 5.2B 48 59 77 98 62 16 1
Alkermes plc 5.0B 89 95 76 80 92 17 1
Cytokinetics, Incorporated 4.1B 63 79 89 51 69 18 1
Novavax, Inc. 4.0B 62 38 63 54 60 19 1
Mirati Therapeutics, Inc. 3.8B 56 58 71 89 65 20 1
Natera, Inc. 3.6B 52 54 56 84 58 21 1
Arrowhead Pharmaceuticals, Inc. 3.4B 60 39 87 96 70 22 1
PTC Therapeutics, Inc. 2.8B 72 53 54 83 72 23 1
Insmed Incorporated 2.4B 79 80 61 89 82 24 1
ACADIA Pharmaceuticals Inc. 2.3B 61 57 98 80 72 25 1
BioCryst Pharmaceuticals, Inc. 1.9B 61 58 54 96 67 26 1
Ironwood Pharmaceuticals, Inc. 1.8B 77 66 67 76 78 27 1
Myriad Genetics, Inc. 1.5B 50 37 82 83 59 28 1
Agios Pharmaceuticals, Inc. 1.2B 85 68 44 46 75 29 1
IVERIC bio, Inc. 1.1B 64 67 44 71 64 30 1
FibroGen, Inc. 1.0B 86 74 48 87 84 31 1
Syndax Pharmaceuticals, Inc. 1.0B 50 41 74 78 57 32 1
ImmunoGen, Inc. 946.1M 77 79 95 95 87 33 1
Enanta Pharmaceuticals, Inc. 922.8M 58 47 84 83 66 34 1
Deciphera Pharmaceuticals, Inc. 914.0M 87 79 95 91 94 35 1
Anavex Life Sciences Corp. 767.1M 69 63 74 71 72 36 1
Sangamo Therapeutics, Inc. 600.0M 85 78 93 83 91 37 1
AnaptysBio, Inc. 586.3M 80 77 92 41 80 38 1
Geron Corporation 566.2M 78 68 49 81 77 39 1
Mersana Therapeutics, Inc. 449.1M 59 69 53 92 65 40 1
Inovio Pharmaceuticals, Inc. 416.9M 67 67 92 44 71 41 1
Arbutus Biopharma Corporation 388.2M 92 93 80 87 95 42 1
Intercept Pharmaceuticals, Inc. 386.3M 87 95 98 89 96 43 1
Anika Therapeutics, Inc. 322.7M 69 67 70 51 63 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 91 82 39 46 77 45 1
Precigen, Inc. 299.1M 82 75 37 85 74 46 1
bluebird bio, Inc. 288.7M 89 77 93 37 83 47 1
Rigel Pharmaceuticals, Inc. 187.5M 42 40 46 40 41 48 1
MacroGenics, Inc. 184.6M 70 53 54 46 65 49 1
Exact Sciences Corporation 7.2B 53 45 80 46 56 50 1
Amicus Therapeutics, Inc. 3.0B 81 80 71 87 85 51 1
CureVac N.V. 2.6B 87 80 90 70 90 52 1
Fate Therapeutics, Inc. 2.4B 64 52 55 48 61 53 1
Abgenix Inc. 2.1B 66 53 45 59 58 54 1
Xenon Pharmaceuticals Inc. 1.9B 82 77 87 92 89 55 1
Iovance Biotherapeutics, Inc. 1.7B 77 66 69 69 77 56 1
Xencor, Inc. 1.6B 96 95 70 95 98 57 1
Emergent BioSolutions Inc. 1.6B 70 53 87 75 75 58 1
Dynavax Technologies Corporation 1.5B 64 48 82 65 68 59 1
Ligand Pharmaceuticals Incorporated 1.5B 86 93 51 78 84 60 1
Aurinia Pharmaceuticals Inc. 1.4B 73 79 92 96 84 61 1
Veracyte, Inc. 1.4B 90 95 46 46 82 62 1
Sierra Oncology, Inc. 1.3B 47 77 38 71 52 63 1
Celldex Therapeutics, Inc. 1.3B 69 63 67 54 69 64 1
CareDx, Inc 1.2B 98 84 40 50 86 65 1
Vericel Corporation 1.1B 64 46 59 73 65 66 1
Avid Bioservices, Inc. 959.5M 80 38 40 50 66 67 1
MannKind Corporation 957.2M 77 56 43 37 66 68 1
Merus N.V. 941.6M 70 71 74 53 71 69 1
Sorrento Therapeutics, Inc. 747.5M 48 63 61 52 52 70 1
Amarin Corporation plc 734.5M 52 40 74 55 55 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 77 81 98 87 87 72 1
Northwest Biotherapeutics, Inc. 682.9M 80 77 81 86 85 73 1
Organogenesis Holdings Inc. 612.1M 76 76 63 55 75 74 1
CTI BioPharma Corp. 603.6M 48 60 74 67 56 75 1
Vanda Pharmaceuticals Inc. 598.8M 66 60 87 51 69 76 1
Eagle Pharmaceuticals, Inc. 546.4M 63 40 97 92 73 77 1
Immatics N.V. 538.7M 82 95 56 99 86 78 1
Agenus Inc. 520.5M 57 43 52 77 58 79 1
Radius Health, Inc. 499.8M 64 40 37 56 57 80 1
Vaxart, Inc. 440.0M 72 56 53 38 65 81 1
Affimed N.V. 415.0M 72 57 95 43 74 82 1
ADMA Biologics, Inc. 396.6M 62 77 74 85 71 83 1
MiMedx Group, Inc. 391.5M 46 48 97 86 60 84 1
Albireo Pharma, Inc. 362.9M 59 68 41 95 63 85 1
AVEO Pharmaceuticals, Inc. 337.5M 94 87 74 83 95 86 1
Zymeworks Inc. 324.7M 52 65 45 83 57 87 1
Heron Therapeutics, Inc. 314.6M 66 74 61 84 71 88 1
Silence Therapeutics plc 313.4M 68 66 72 69 69 89 1
AC Immune SA 299.8M 66 77 79 63 68 90 1
Viridian Therapeutics, Inc. 293.2M 72 87 43 45 65 91 1
Sutro Biopharma, Inc. 245.5M 83 67 64 50 74 92 1
Chimerix, Inc. 178.4M 80 84 95 47 83 93 1
DermTech, Inc. 165.3M 60 51 45 86 58 94 1
Gelesis Holdings, Inc. 111.5M 64 90 92 98 80 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 58 72 43 71 58 96 1
INSYS Therapeutics, Inc. 3.2M 75 78 87 52 73 97 1

This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.